The global rheumatic heart disease market is anticipated to grow at a CAGR of 6.0% during the forecast period (2021-2027). Global rheumatic heart disease is segmented based on treatment, type, diagnostics tests, and end-users. Based on the type, the global rheumatic heart disease market is segmented into valve, myocarditis, and pericarditis. Besides, the valve is bifurcated into the aortic valve and mitral valve. The valve segment of the global rheumatic heart disease market is projected to hold the most substantial share over the forecast period. The factor that is driving the growth of segment includes rising FDA approvals, the market players initiatives, among others. For instance, in December 2020, In India, Abbott has announced the launch of its clip-delivery system, a minimally invasive heart valve repair product for mitral regurgitation. The system connects parts of the mitral valve's leaflets, or flaps, to minimize blood backflow (known as mitral regurgitation, or MR), allowing the heart to pump oxygenated blood more effectively.
Browse the full report description of "Global Rheumatic heart disease Market Size, Share & Trends Analysis Report by Treatment (Antibiotics Medication, Anti-Convulsant Medication, Anti-Inflammatory Treatment, and Surgical Treatment), By Type (Valve, Myocarditis, and Pericarditis), By Diagnostics Tests (Electrocardiogram, Echocardiogram, Blood Test, and Imaging), By End-User (Hospitals and Clinics, Diagnostic Centres, and Research centers) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/rheumatic-heart-disease-market
In March 2021, Keystone Heart, Ltd., a medical device innovator dedicated to redefining the quality in structural heart treatment, had announced the agreement done with InterValve Medical Inc., a Venus Medtech company, focuses on offering pioneering aortic valvuloplasty balloon catheters that dilate stenotic valve leaflets and the surrounding native tissue to increase aortic valve area and systemic blood flow. This agreement between the companies was done to distribute and market their balloon aortic valvuloplasty items in the US. V8 and TAV8 balloon catheters, the company's trademark devices, are the FDA-cleared aortic valvuloplasty balloon catheters with a unique 8-shaped design that is more in line with the anatomical structure of the aortic valve than conventional long cylindrical aortic valvuloplasty balloons. Both balloon catheters are used for stand-alone valvuloplasty procedures as well as procedures before and after transcatheter self-expanding heart valve repair. However, the continuous improvement by leading market players in global rheumatic heart disease drugs and development in biotechnology has brought new opportunities to the global rheumatic heart disease market.
Market Coverage
o By Treatment
o By Type
o By Diagnostics Tests
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Rheumatic Heart Disease Market Report Segment
By Treatment
By Type
o Aortic Valve
o Mitral Valve
By Diagnostics Test
By End-User
Global Rheumatic Heart Disease Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/rheumatic-heart-disease-market